Eugene Kennedy
Technik-/Wissenschafts-/F&E-Leiter bei CARISMA THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Eugene Kennedy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CARISMA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.05.2024 | - |
Karriereverlauf von Eugene Kennedy
Ehemalige bekannte Positionen von Eugene Kennedy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GALERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2022 | 01.09.2023 |
| LUMOS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 | 06.03.2021 |
| Thomas Jefferson University | Corporate Officer/Principal | 01.01.2006 | 01.12.2013 |
| Innovative Cellular Therapeutics, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
The Hope Funds for Cancer Research
 The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Direktor/Vorstandsmitglied | - | - |
| LUMOS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 14.11.2017 | - |
Ausbildung von Eugene Kennedy
| University of Virginia | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 10 |
Operativ
| Chief Tech/Sci/R&D Officer | 5 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| GALERA THERAPEUTICS, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
The Hope Funds for Cancer Research
The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Commercial Services |
| Innovative Cellular Therapeutics, Inc. |
- Börse
- Insiders
- Eugene Kennedy
- Erfahrung
